These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15257626)

  • 21. Trospium chloride: an anticholinergic quaternary ammonium compound for the treatment of overactive bladder.
    Zinner NR
    Expert Opin Pharmacother; 2005 Jul; 6(8):1409-20. PubMed ID: 16013990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tolterodine use for symptoms of overactive bladder.
    Ruscin JM; Morgenstern NE
    Ann Pharmacother; 1999 Oct; 33(10):1073-82. PubMed ID: 10534221
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder.
    Yamada S; Ito Y; Nishijima S; Kadekawa K; Sugaya K
    Pharmacol Ther; 2018 Sep; 189():130-148. PubMed ID: 29709423
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elevating our therapeutic expectations in overactive bladder.
    Sand PK
    J Am Acad Nurse Pract; 2004 Oct; 16(10 Suppl):8-11. PubMed ID: 15543927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in the United Kingdom.
    Nazir J; Maman K; Neine ME; Briquet B; Odeyemi IA; Hakimi Z; Garnham A; Aballéa S
    Value Health; 2015 Sep; 18(6):783-90. PubMed ID: 26409605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Overactive bladder--a practical approach to evaluation and management.
    Madersbacher H
    J Med Liban; 2004; 52(4):220-6. PubMed ID: 16432986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized trial comparing the use of tolterodine or weighted vaginal cones in women with overactive bladder syndrome.
    Yüce T; Dökmeci F; Çetinkaya ŞE
    Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():91-7. PubMed ID: 26720597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
    Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
    J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Which muscarinic receptor is important in the bladder?
    Yamanishi T; Chapple CR; Chess-Williams R
    World J Urol; 2001 Nov; 19(5):299-306. PubMed ID: 11760777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolterodine: a review of its use in the treatment of overactive bladder.
    Clemett D; Jarvis B
    Drugs Aging; 2001; 18(4):277-304. PubMed ID: 11341475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
    Garely AD; Lucente V; Vapnek J; Smith N
    Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overactive bladder.
    Kavia R; Mumtaz F
    J R Soc Promot Health; 2005 Jul; 125(4):176-9. PubMed ID: 16094929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder.
    Kelleher CJ; Reese PR; Pleil AM; Okano GJ
    Am J Manag Care; 2002 Dec; 8(19 Suppl):S608-15. PubMed ID: 12516955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder.
    Ko Y; Malone DC; Armstrong EP
    Pharmacotherapy; 2006 Dec; 26(12):1694-702. PubMed ID: 17125433
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of anti-muscarinic agents for the treatment of overactive bladder.
    Armstrong EP; Malone DC; Bui CN
    J Med Econ; 2012; 15 Suppl 1():35-44. PubMed ID: 22998646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
    Wagg A; Wyndaele JJ; Sieber P
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.
    Hay-Smith J; Herbison P; Ellis G; Moore K
    Cochrane Database Syst Rev; 2002; (3):CD003781. PubMed ID: 12137711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.